Peptide policy: a field note for comparing care
An October field note for reading an announcement alongside the offer in front of you.
Start with the federal document
The Register notice describes a section 503A enforcement approach for state-licensed pharmacies, federal facilities and licensed physicians while rulemaking proceeds. It does not announce permanent bulk-list placement or section 503B authority. HHS may reconsider for safety signals or product-quality problems.
Register noticeEach peptide’s final inclusion or exclusion rule ends discretion.
HHS policyAt our October 29 check, the Federal Register entry was unpublished, with publication scheduled for October 30. Its notice calls the policy draft and nonbinding. Neither a filing nor a publication schedule establishes an effective date for this article.
Register noticeMatch the preparation
Read across a row before moving down the list. The first column identifies the preparation; the second keeps the route beside it. Then read the numbered conditions together. This layout is a reading aid, not a way to approve an offer by matching one word.
Read across the row
Scroll sideways to read the full table.
| Form | Routes |
|---|---|
| BPC-157 acetate | Subcutaneous, intramuscular, oral, topical; excludes intravenous use |
| TB-500 acetate; thymosin beta-4 fragment | Subcutaneous or intramuscular injection |
| Epitalon acetate | Subcutaneous or intramuscular injection; intermittent courses |
| Semax free base | Intranasal |
| KPV acetate | Oral or topical |
| MOTS-c acetate | Subcutaneous or intramuscular injection |
Read the safeguards together
Conditions in the document
- Appendix A substance.
- Appendix B sequence, structure, molecular weight, formula and routes.
- Source: section 510 registered; valid certificate of analysis (COA) with Appendix B tests.
- Original bulk manufacturer: section 510 registration, CGMP and FD&C compliance; physical address on COA. Registered intermediaries document manufacturer and COA validation.
- Report products, serious events regardless of causality, and quality issues to FDA and compounding and destination states; events and issues through MedWatch. Labels explain reporting. Product reports: ingredient, strength per unit, original manufacturer, facility identifier, form and route.
- Label: “This is a compounded drug product. Not for resale.”
- One active ingredient, from Appendix A.
- Oral formulations: document adequate human bioavailability for each supplied formulation.
- Co-packaged or drug-containing delivery devices: only FDA-510(k)-cleared syringes; noninjectable application unresolved.
- Other FD&C requirements, sanitary compounding and patient-specific prescriptions.
Bring the comparison back to the pharmacy
FDA does not approve compounded products before sale for safety, effectiveness or quality. Poor compounding can introduce contamination or an incorrect amount of active ingredient, with serious consequences.
Compounding questionsState pharmacy boards generally oversee state-licensed pharmacies outside the 503B outsourcing category day to day; FDA also conducts surveillance and for-cause inspections. FDA primarily oversees registered 503B outsourcing facilities.
Compounding questionsThe finished-product distinction also matters: drugs meeting section 503A’s conditions are exempt from current good manufacturing practice (CGMP); 503B outsourcing-facility drugs are subject to it.
Compounding questionsFor an online offer, identify the actual dispensing pharmacy and check its state license. A familiar brand does not identify who made a particular preparation.
Compounding questionsRead the company announcement separately
On October 29, Hims & Hers introduced a Peptides+ preview and invited people to join a launch list. It described plans for sermorelin, glutathione, B12, NAD+ and L-carnitine, with BPC-157 and TB-500 later, when allowable. That is a therapy menu, not a list made entirely of peptides.
Company announcementCompany plans remain distinct from a verified service. The announcement’s forward-looking disclosure identifies uncertainty around launch timing, availability, manufacturing and clinical evidence. We have not tested ordering, prescribing, fulfillment, geographic eligibility, prices or any offered formulation.
Company announcementPeptides+ is a separate announcement; it does not verify what is available through the Hims & Hers GLP-1 program.
Company announcementQuestions to take further
What should I recheck after the scheduled publication date?
Check the actual published notice and any subsequent revisions. The captured notice invites comments for two weeks after publication; we have not converted that relative window into a firm deadline.
Register noticeDoes a waitlist establish access where I live?
No. Treat it as an invitation to receive launch information. Any later offer needs its own product, prescribing and dispensing checks.
Company announcementOur reading note
We would compare an actual offer in this order: its precise preparation, the named prescriber and dispensing pharmacy, your location, and the care team’s explanation of why it is being proposed. An unanswered question should remain unanswered in a comparison; replacing it with a reassuring headline makes the comparison less useful.
This AI-assisted editorial reading of policy and company documents has not been reviewed by a clinician. We have not audited pharmacies, verified licenses or state-specific compliance, tested products, inspected chemical drawings, or independently reviewed the clinical studies behind the policy. Older library entries retain their own evidence dates. This field note supplies no dosing instructions or treatment recommendation.
Sources
- HHS policyHHS · Checked
- Register noticeFederal Register · Checked
- Company announcementHims & Hers · Checked
- Compounding questionsFDA · Checked